[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:alk-positive-large-b-cell-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":22,"states":23},"ALK-Positive Large B-Cell Lymphoma",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[11],"Phase 1","RECRUITING","2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[19],"Phase 2","2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.687370Z",[],[]]